Glaucoma News and Research

Latest Glaucoma News and Research

Sun Pharma, Intrexon partner to develop controllable gene-based therapies for ocular diseases

Sun Pharmaceutical Industries Ltd., an international specialty pharmaceutical company focused on chronic diseases, through its subsidiary, and Intrexon Corporation, a leader in synthetic biology, today announced the formation of a joint venture to develop controllable gene-based therapies for the treatment of ocular diseases that cause partial or total blindness in millions of people worldwide.

1 Oct 2013

Optic flow enables perception despite blur image

Blurred images that are unidentifiable as still pictures become understandable once the images are set in motion. That's because of a phenomenon called "optic flow"—which may be especially relevant as a source of visual information in people with low vision, reports a study 'With an Eye to Low Vision: Optic Flow Enables Perception Despite Image Blur' in the October issue of Optometry and Vision Science official journal of the American Academy of Optometry.

27 Sep 2013

IRIDEX's MicroPulse Laser Therapy to be featured at EURETINA and ESCRS conferences

IRIDEX today announced a number of key international conferences and workshops that will feature its proprietary MicroPulse Laser Therapy for the treatment of diabetes and glaucoma related disorders.

26 Sep 2013

New laser provides better treatment for eye diseases in diabetes patients

A new laser is helping experts at the Truhlsen Eye Institute at the University of Nebraska Medical Center provide better treatment for eye diseases. This advanced laser can prevent blindness for some patients with serious conditions.

24 Sep 2013

Longer looks: Phenomenal growth of the Cleveland Clinic prompts hopes for the city; the bittersweet decision to donate organs

Delos M. "Toby" Cosgrove arrived at the Cleveland Clinic in 1975 as an "incredibly poor" 34-year-old dreaming of a life as a cardiac surgeon. … As the years passed he became well-known for pioneering the replacement of heart valves, eventually assuming the chair of the department of cardiothoracic surgery.

From Medtronic 5 Sep 2013

Prevalence for major eye disease is higher in people with common sleep disorder

Researchers in Taiwan have discovered that people with sleep apnea are far more likely to develop glaucoma compared to those without the sleep condition. The results of this study, which is the first to calculate the risk of the disease among people with the sleep disorder following diagnosis, is published in this month's edition of Ophthalmology, the journal of the American Academy of Ophthalmology.

8 Aug 2013

Forest Laboratories, Pierre Fabre Laboratories announce that FETZIMA gets FDA approval for MDD

Forest Laboratories, Inc. and Pierre Fabre Laboratories announced today that FETZIMA (levomilnacipran extended-release capsules), a once-daily serotonin and norepinephrine reuptake inhibitor, discovered by Pierre Fabre Laboratories and co-developed by Forest Laboratories, Inc. was approved by the U.S. Food and Drug Administration for the treatment of Major Depressive Disorder in adults.

26 Jul 2013

Research roundup: Eye care disparities; more complications for Medicaid patients after spine surgery; the cost to states opting against Medicaid expansion

After analyzing 2003-2004 data of patients who underwent spinal surgery at two medical institutions, they found that Medicaid beneficiaries were at much higher risk of experiencing any type of complication than patients who are privately insured. "The results of our study further support the growing body of literature that Medicaid patients have higher rates of complications," the authors write. When evaluating patients and considering the likelihood of complications, "Medicaid status should be considered as well," they concluded (Hacquebord et al., 7/15).

20 Jul 2013

Bausch + Lomb obtains option to license MIM-D3 for treatment of dry eye syndrome

Bausch + Lomb, the global eye health company, and Mimetogen Pharmaceuticals Inc. today announced that Bausch + Lomb has acquired an option to license an investigational compound currently in Phase 2 development for the treatment of dry eye syndrome, a condition that affects millions of people worldwide.

19 Jul 2013

UC Riverside professor receives grant to study potential treatment for age-related macular degeneration

A University of California, Riverside bioengineering professor has received a two-year, $120,000 grant to search for chemical compounds that have the potential to treat age-related macular degeneration.

12 Jul 2013

Tel Aviv researcher says lessons from Israel's health-care system could optimize eye health

According to the World Health Organization, 80% of blindness is preventable or treatable - but it remains a severe health concern across the globe, even in industrialized countries.

11 Jul 2013

visualFields package: A tool for analysis and visualization of visual fields

Vision researchers have developed new software that will analyze visual fields in an open-source platform to improve and encourage collaborative research among independent labs. An analysis of the free tool is presented in a Journal of Vision (JOV) paper, The visualFields package: A tool for analysis and visualization of visual fields.

10 Jul 2013

Diclegis delayed-release tablets for NVP treatment now eligible for Medicaid coverage

Duchesnay USA today announced that Diclegis (doxylamine succinate 10mg, pyridoxine hydrochloride 10mg) delayed-release tablets for the treatment of nausea and vomiting of pregnancy, more commonly known as morning sickness, is now available for coverage under the state and federal Medicaid program effective July 1st, 2013.

9 Jul 2013

EyeTechCare's EyeOP1 device to be installed in four healthcare facilities in France

EyeTechCare SA, which develops non-invasive therapeutic medical devices for the ophthalmology market based on the use of ultrasound, today announces that its EyeOP1 device is to be installed in a number of hospitals in France, namely Lille University Hospital, Grenoble University Hospital and the Quinze-Vingts and Saint-Joseph hospitals in Paris. The first use of this device for the routine treatment of glaucoma patients is slated from July onwards.

4 Jul 2013

Discovery of cells movement inside body may provide information to scientists about disease mechanism s

A new discovery about how cells move inside the body may provide scientists with crucial information about disease mechanisms such as the spread of cancer or the constriction of airways caused by asthma.

24 Jun 2013

pSivida reports that NICE issues draft guidance for use of ILUVIEN for pseudophakic patients with DME

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that the United Kingdom's National Institute for Health and Care Excellence issued draft guidance recommending ILUVIEN for the treatment of pseudophakic patients (those who have undergone prior cataract surgery) with chronic diabetic macular edema considered insufficiently responsive to available therapies.

15 Jun 2013

Prostaglandin analogues cause droopy eyelids, new study finds

Prostaglandin analogues, drugs which lower intraocular pressure, are often the first line of treatment for people with glaucoma, but their use is not without risks.

22 May 2013

Boehringer Ingelheim to highlight respiratory research work at ATS 2013

Boehringer Ingelheim will contribute to advancing the scientific discussion in respiratory disease at the American Thoracic Society International Conference in Philadelphia, PA, May 17 – 22.

20 May 2013

Study: VEGF inhibitor appears to improve glaucoma surgical outcomes

The most common cause of failure after glaucoma surgery is scarring at the surgical site, so researchers are actively looking for ways to minimize or prevent scar formation. Previous work had suggested that vascular endothelial growth factor (VEGF) activates fibrosis, whereas VEGF inhibition results in reduced scar formation and better surgical results.

18 May 2013

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

As part of the company's commitment to chronic obstructive pulmonary disease patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals and patients that the transition to COMBIVENT RESPIMAT (ipratropium bromide and albuterol) Inhalation Spray for the maintenance treatment of COPD is nearly complete.

18 May 2013

Glaucoma News and Research

Latest Glaucoma News and Research

Sun Pharma, Intrexon partner to develop controllable gene-based therapies for ocular diseases

Optic flow enables perception despite blur image

IRIDEX's MicroPulse Laser Therapy to be featured at EURETINA and ESCRS conferences

New laser provides better treatment for eye diseases in diabetes patients

Longer looks: Phenomenal growth of the Cleveland Clinic prompts hopes for the city; the bittersweet decision to donate organs

Prevalence for major eye disease is higher in people with common sleep disorder

Forest Laboratories, Pierre Fabre Laboratories announce that FETZIMA gets FDA approval for MDD

Research roundup: Eye care disparities; more complications for Medicaid patients after spine surgery; the cost to states opting against Medicaid expansion

Bausch + Lomb obtains option to license MIM-D3 for treatment of dry eye syndrome

UC Riverside professor receives grant to study potential treatment for age-related macular degeneration

Tel Aviv researcher says lessons from Israel's health-care system could optimize eye health

visualFields package: A tool for analysis and visualization of visual fields

Diclegis delayed-release tablets for NVP treatment now eligible for Medicaid coverage

EyeTechCare's EyeOP1 device to be installed in four healthcare facilities in France

Discovery of cells movement inside body may provide information to scientists about disease mechanism s

pSivida reports that NICE issues draft guidance for use of ILUVIEN for pseudophakic patients with DME

Prostaglandin analogues cause droopy eyelids, new study finds

Boehringer Ingelheim to highlight respiratory research work at ATS 2013

Study: VEGF inhibitor appears to improve glaucoma surgical outcomes

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Glaucoma News and Research

Latest Glaucoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in